Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Retrospective examination of pseudoprogression in IDH mutant gliomas

Autor: Wetzel, Ethan A, Farrell, Matthew J, Eldred, Blaine SC, Liu, Vicki, Saha, Ishan, Zapanta Rinonos, Serendipity, Prins, Terry, Li, Tie, Cao, Minsong, Hegde, John, Kaprealian, Tania, Khanlou, Negar, Liau, Linda M, Nghiemphu, Phioanh Leia, Cloughesy, Timothy Francis, Chong, Robert A, Ellingson, Benjamin M, Lai, Albert

Publikováno v: Neuro-oncology advances, vol 5, iss 1

BackgroundTumor surveillance of isocitrate dehydrogenase (IDH) mutant gliomas is accomplished via serial contrast MRI. When new contrast enhancement (CEnew) is detected during postsurgical surveillance, clinicians must assess whether CEnew indicates

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::234200d4bfe29b80378d5ca52ad8a846
https://escholarship.org/uc/item/5pd3r06c

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma.

Autor: Lai TJ; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Sun L; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Li K; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Prins TJ; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Treger J; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Li T; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Sun MZ; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Nathanson DA; Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California., Liau LM; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California., Lai A; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California., Prins RM; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.; Parker Institute for Cancer Immunotherapy, San Francisco, California., Everson RG; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Jul 01; Vol. 4 (7), pp. 1834-1849.